Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.2% | 0.5% | 6.1% |
| 2025 |
|---|
| 6.1% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.2% | 0.5% | 6.1% |
| 2025 |
|---|
| 6.1% |
The Gabelli ABC Fund returned 0.45% in Q4 2025, bringing full-year returns to 6.07%. The Fund focuses on arbitrage strategies and event-driven situations, benefiting from a robust M&A environment that saw $4.6 trillion in announced transactions for 2025, a 49% increase from the previous year. The quarter was led by megadeals, including Netflix's $83 billion acquisition of Warner Bros. Discovery, though Paramount Skydance intervened with a higher $108 billion proposal. Technology, industrials, and financials dominated M&A activity, accounting for over $2 trillion in deals. Top contributors included Surmodics, Pan American Silver, and Fox, while detractors included Perrigo and National Fuel Gas. The Fund successfully closed several biotech deals including Akero Therapeutics and Metsera acquisitions. Despite macro headwinds from government shutdowns and geopolitical tensions, the continued economic resiliency and benign credit environment support ongoing M&A activity into 2026.
The Fund focuses on arbitrage strategies investing in event driven situations such as announced mergers, spin-offs, split-ups, liquidations, and reorganizations while holding significant assets in U.S. Treasury bills for quick, non-market correlated opportunities.
As the new year begins, the expectation for positive impact on the economy from last year's tax bill and tariff dynamics will allow strong M&A activity to continue well into 2026.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Feb 18 2026 | 2025 Q4 | CFLT, EXAS, FOX, FRGE, GTLS, HOLX, KKR, KMB, KVUE, LEN, NEM, NFG, NFLX, PAAS, PSKY, TGNA, TXNM, WBD | arbitrage, healthcare, industrials, M&A, private equity, technology |
GTCH EXAS HOLX ALE |
Multiple biotech and pharmaceutical M&A deals closed during the quarter, including Akero Therapeutics acquired by Novo Nordisk for $54.00 per share plus CVR, Metsera acquired… |
| Nov 16 2025 | 2025 Q3 | AMSF, GTLS, SAND | arbitrage, M&A, regulation, Spreads, volatility |
ECG US OR US |
The letter emphasizes merger arbitrage as a steady, low-volatility strategy benefiting from elevated global M&A activity fueled by lower rates, improved trade clarity, and lighter… |
| Jun 30 2025 | 2025 Q2 | 1ITCI IM, DNB, INFA, SWTX | arbitrage, M&A, Merger, Spread, valuation | SWTX | - |
| Mar 31 2025 | 2025 Q1 | BECN, FYBR, LGTY | - | - | - |
| Dec 31 2024 | 2024 Q4 | ALE, AXNX* MM, CPRX, NAPA, SCWX | - | - | - |
| Sep 30 2024 | 2024 Q3 | CHUY, INST | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
BiopharmaSector out of favor due to political factors leading to lower industry R&D spend. Manager believes society will continue to need new drugs and health innovations, expecting capital to return and R&D spend to reaccelerate. Initiated diversified basket allocation via ETFs and service-based businesses. |
Biotechnology Pharmaceuticals Drug Development Healthcare Innovation R&D |
Capital MarketsCapital markets are wide open with elevated levels of debt issuance, equity offerings, and M&A volumes. Falling interest rates, rising equity prices, and improving corporate confidence are driving an optimistic outlook for deals, which should benefit advisory firms, rating agencies, and alternative asset managers. |
Investment Banking M&A Debt Issuance Advisory Alternative Assets | |
| 2025 Q3 |
Innovation |
|
| 2025 Q2 |
ArbitrageThe arbitrage and opportunistic book contributed approximately one-third of total gross returns, with activity spread across single-name catalyst shorts, merger arbitrage, and volatility positions. Notable contributors included Core Scientific/CoreWeave merger arbitrage adding +550 basis points and a long-volatility position in Alphabet contributing +630 basis points. |
Merger arbitrage Volatility Catalyst Opportunistic Trading |
Merger |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2025 | Fund Letters | Mario J. Gabelli | ECG US | Everus Construction Group, Inc. | Industrials | Construction & Engineering | Bull | NYSE | backlog, construction, data centers, Electrification, infrastructure | Login |
| Nov 16, 2025 | Fund Letters | Mario J. Gabelli | OR US | OR Royalties Inc. | Materials | Precious Metals Royalty & Streaming | Bull | NYSE | Gold, low leverage, Optionality, royalties, Streaming | Login |
| Jun 30, 2025 | Fund Letters | Mario J. Gabelli | SWTX | SpringWorks Therapeutics, Inc. | Health Care | Biotechnology | Bull | NASDAQ | acquisition, Approval, arbitrage, Biotech, cashflow, Oncology, pipeline, Spread | Login |
| Feb 18, 2026 | Fund Letters | Mario J. Gabelli | GTCH | Chart Industries, Inc. | Industrials | Industrial Machinery | Bull | New York Stock Exchange | acquisition, arbitrage, energy, Industrials, LNG | Login |
| Feb 18, 2026 | Fund Letters | Mario J. Gabelli | EXAS | Exact Sciences Corporation | Health Care | Health Care Services | Bull | NASDAQ | diagnostics, growth, Oncology, Reimbursement, Screening | Login |
| Feb 18, 2026 | Fund Letters | Mario J. Gabelli | HOLX | Hologic, Inc. | Health Care | Health Care Equipment | Bull | NASDAQ | arbitrage, cashflow, diagnostics, Imaging, private equity | Login |
| Feb 18, 2026 | Fund Letters | Mario J. Gabelli | ALE | ALLETE, Inc. | Utilities | Electric Utilities | Bull | New York Stock Exchange | arbitrage, cash, infrastructure, Regulation, utilities | Login |
| TICKER | COMMENTARY |
|---|---|
| CFLT | CFLT, one of infrastructure software investments, reported a slightly disappointing quarter. The disappointment, in our opinion, was largely cosmetic. The market, however, severely punished the stock, treating the mild disappointment on one key performance indicator as if it was existential. We disagreed and used the opportunity to make CFLT one of our biggest positions, believing this to be a very strategic asset. Late in the fourth quarter we were validated when IBM announced a bid to acquire the company for a 35% premium. |
| EXAS | The largest single contributor was Exact Sciences, which was acquired for a significant premium by Abbot Laboratories in November, resulting in an +86% return in the quarter for one of our higher-conviction positions. |
| GTLS | Chart Industries Inc. makes specialized equipment for storing, transporting and processing gases for the LNG and hydrogen industries. GTLS was in the process of combing with Flowserve in a merger of equals. But on July 29, Baker Hughes agreed to acquire GTLS for $210.00 per share in cash – topping the Flowserve merger. |
| HOLX | We note that both CADE and HOLX both agreed to be acquired, with the deals pending closure in 2026. We believe both deals will close and elected to hold the positions into the close, as there is likely upside for each. |
| KKR | Over the prior two years, KKR was one of the Fund's strongest contributors. From the end of 2022 through the end of 2024, the shares more than tripled, rising roughly 80% in 2023 and another 80% in 2024, as the market began to recognize the earnings power of its asset-management and insurance platforms. This year, the stock told a different story: in 2025 it was down about 13% and was roughly 23% below its January peak. Strip away the stock-price swings, and the business itself has continued to grow. Fee-related earnings, insurance earnings, and long-dated capital have all moved higher, even as market sentiment toward rates, credit, and capital flows into alternatives has become more cautious. |
| KMB | One holding that ran into difficulties last quarter is Kimberly Clark (KMB), the tissue company behind well-known brands such as Huggies, Cottonelle, and Kleenex. The consumer products giant saw its shares fall more than 14% in November, not because of poor results or sub-par execution. Instead, the stock sank immediately after KMB announced its $48.7 billion acquisition of Kenvue, the consumer health company spun off from Johnson & Johnson which sells Tylenol, Neutrogena, Band-Aid and Listerine. We disagree with management's capital allocation decision, as it takes KMB into new categories and poses significant integration risk. We find it unfortunate that management made such an aggressive move after executing well against an internally focused playbook that positioned KMB for value creation in the coming years. We fear that the Kenvue deal makes the company bigger, not necessarily better. We trimmed the position in response to the Kenvue announcement. However, we balance deal-related question marks against a valuation of 13 times earnings (a historically wide discount to peers), better market share trends and improved margin performance in recent years. |
| KVUE | Kimberly-Clark's $49 billion acquisition of Kenvue. |
| LEN | LEN: $5B authorized January 2024; $4B completed |
| NEM | Newmont delivered +18% performance over the quarter, contributing meaningfully to portfolio returns as gold gained another 12%, taking its 2025 gains to an extraordinary 64%. |
| NFG | National Fuel Gas Co. is a gas and pipeline utility with a growing exploration and production business. The gas utility serves 754,000 customers in Buffalo, New York, and Erie and Sharon, Pennsylvania. The pipeline & storage (P&S) business operates 3,000 miles of pipe and 34 storage facilities primarily in the state of New York. The E&P business, Seneca Resources, operates in Appalachia (where it owns 1.2 million net acres), primarily in the Marcellus and Utica shales and ended FY 2025 with nearly 5.0 Tcfe of proved gas reserves, making it one of the most resource-rich utilities in the U.S. These reserves are strategically important as natural gas demand in the Northeast accelerates, driven in part by rising electricity consumption from data centers and AI-related load growth. NFG's extensive pipeline and storage network further enhances the value of its upstream assets by providing reliable access to premium regional markets. Higher gas production and prices have helped drive very strong EPS and cash flow growth in recent years and will continue given legacy hedges roll off and are replaced at higher prices. NFG's pending $2.6 billion acquisition of CenterPoint Energy's Ohio gas utility will roughly double NFG's regulated utility rate base, expand its customer footprint, and increase the percentage of earnings derived from regulated operations. |
| NFLX | NFLX was the portfolio's largest detractor in 4Q25 following investor concerns around near-term subscriber growth and rising content spending. While revenue grew approximately 10% year-over-year, management guided to slower net subscriber additions in North America and Europe after recent price increases, and margins were pressured by elevated investment in live sports and international content. |
| PAAS | Pan American Silver provides diversified exposure to silver and gold across the Americas. Our position was established following Pan American's acquisition of a long-standing pool holding, MAG Silver, in May 2025, which expanded the company's scale and reserve base. Even excluding recent price volatility, company all-in silver production costs remain around US$15 per ounce, supporting profitable production across a wide range of price environments. |
| PSKY | By comparison, we exited Paramount Skydance Corp (PSKY) on strong price appreciation, prompting us to realize gains once the stock reached our estimate of its private market value. |
| WBD | Warner Bros Discovery (WBD) was the top contributor during the quarter. The U.S.-headquartered media company's stock price surged as multiple parties submitted offers to acquire all or part of the business. Following several rounds of bidding, WBD announced an agreement to sell its Streaming and Studios business to Netflix, while spinning the Global Networks business to shareholders. Paramount Skydance subsequently made a direct $30 per share offer to shareholders for the entire company. We are pleased with the steps the WBD board has taken thus far to unlock shareholder value. We will continue to closely monitor developments as this bidding war unfolds. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||